Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Daratumumab Receives FDA Approval for Transplant-Eligible Multiple Myeloma

Daratumumab Receives FDA Approval for Transplant-Eligible Multiple Myeloma

On 26 September 2019, the US Food and Drug Administration (FDA) approved treatment for newly diagnosed adults eligible for autologous stem cell transplantation with multiple myeloma, in combination with bortezomib, thalidomide and dexamethasone: daratumumab (Darzalex) , a monoclonal antibody drug.

Darzalex was first approved in 2015, for multiple myeloma patients previously treated with proteasome inhibitors and immunomodulatory drugs, becoming the first approved monoclonal antibody drug for this disease. Many myeloma cells have abundant CD38 on their surfaces. CD38 has functions including signaling and tissue adhesion. Daratumumab binds CD38, inhibits its activity and causes tumor cell breakdown and destruction.

The CASSIOPEIA Study

An open-label, randomized, active-controlled phase 3 clinical trial , CASSIOPEIA compared newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation in two arms:

  • Induction arm: daratumumab combined with bortezomib, thalidomide and dexamethasone (DVTd),
  • Consolidation arm: bortezomib, thalidomide and dexamethasone (VTd).

Approval is based on CASSIOPEIA data, including progression-free survival (PFS), post-transplant day 100 stringent complete response (sCR), and post-transplant day 100 complete response (CR) rate.

Results

  • PFS was better in the daratumumab arm than the VTd arm
  • Median follow-up was 18.8 months, and median PFS had not been reached in either arm.
  • DVTd reduced progression or death risk by 53% compared with VTd alone
  • Post-transplant day 100 sCR was 28.9% in the DVTd arm and 20.3% in the VTd arm.

In newly diagnosed myeloma patients receiving daratumumab with bortezomib, thalidomide and dexamethasone, the most common (20%) side effects were infusion reactions, peripheral sensory neuropathy, constipation, asthenia, nausea, peripheral neuropathy, peripheral edema, pyrexia and paresthesia. Effects occurring at least 5% more frequently in the DVTd arm were infusion reactions, nausea, neutropenia, thrombocytopenia, lymphopenia and cough. There was no significant difference in the number or types of serious side effects between arms.

The recommended daratumumab dose is 16 mg / kg.

Sources

FDA approves daratumumab for transplant-eligible multiple myeloma.
fda.gov - 26 September 2019

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Daratumumab Receives FDA Approval for Transplant-Eligible Multiple Myeloma

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy